TY - JOUR
T1 - Enhanced insulin sensitivity in skeletal muscle and liver by physiological overexpression of SIRT6
AU - Anderson, Jason G.
AU - Ramadori, Giorgio
AU - Ioris, Rafael M.
AU - Galiè, Mirco
AU - Berglund, Eric D.
AU - Coate, Katie C.
AU - Fujikawa, Teppei
AU - Pucciarelli, Stefania
AU - Moreschini, Benedetta
AU - Amici, Augusto
AU - Andreani, Cristina
AU - Coppari, Roberto
N1 - Funding Information:
Grants or fellowships supporting the writing of the paper: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (graduate student fellowship to R.M.I.), Juvenile Diabetes Research Foundation (Post-doctoral fellowship 3-2011-405 to T.F.), American Heart Association (Scientist Development Grant 14SDG17950008 to T.F.), European Commission (Marie Curie Career Integration Grant 320898 and ERC-Consolidator Grant 614847 to R.C.), and the Swiss National Science Foundation (310030_146533/1 to R.C.). This work has also received support from the Louis-Jeantet Foundation and the Fondation Pour Recherches Medicales of the University of Geneva (to R.C.).
Funding Information:
We thank Carolyn Heckenmeyer, Ariane Widmer, and Anne Charollais in the Coppari laboratory for technical support, Dr. Raul Mostoslavsky at Harvard Medical School for providing the Sirt6 null mice, the transgenic core facility at the University of Texas Southwestern Medical Center (USA), and Dr. Christelle Veyrat-Durebex at the glucose/insulin clamp platform at University of Geneva (Switzerland) ( http://www.medecine.unige.ch/phenotypage/clampglucose.php ). This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (graduate student fellowship to R.M.I.), Juvenile Diabetes Research Foundation (Post-doctoral fellowship 3-2011-405 to T.F.), American Heart Association (Scientist Development Grant 14SDG17950008 to T.F.), European Commission (Marie Curie Career Integration Grant 320898 and ERC-Consolidator Grant 614847 to R.C.), and the Swiss National Science Foundation ( 310030_146533/1 to R.C.). This work has also received support from the Louis-Jeantet Foundation and the Fondation Pour Recherches Medicales of the University of Geneva (to R.C.).
Publisher Copyright:
© 2015 The Authors.
PY - 2015/11
Y1 - 2015/11
N2 - Objective: Available treatment for obesity and type 2 diabetes mellitus (T2DM) is suboptimal. Thus, identifying novel molecular target(s) exerting protective effects against these metabolic imbalances is of enormous medical significance. Sirt6 loss- and gain-of-function studies have generated confounding data regarding the role of this sirtuin on energy and glucose homeostasis, leaving unclear whether activation or inhibition of SIRT6 may be beneficial for the treatment of obesity and/or T2DM. Methods: To address these issues, we developed and studied a novel mouse model designed to produce eutopic and physiological overexpression of SIRT6 (Sirt6BAC mice). These mutants and their controls underwent several metabolic analyses. These include whole-blood reverse phase high-performance liquid chromatography assay, glucose and pyruvate tolerance tests, hyperinsulinemic-euglycemic clamp assays, and assessment of basal and insulin-induced level of phosphorylated AKT (p-AKT)/AKT in gastrocnemius muscle. Results: Sirt6BAC mice physiologically overexpress functionally competent SIRT6 protein. While Sirt6BAC mice have normal body weight and adiposity, they are protected from developing high-caloric-diet (HCD)-induced hyperglycemia and glucose intolerance. Also, Sirt6BAC mice display increased circulating level of the polyamine spermidine. The ability of insulin to suppress endogenous glucose production was significantly enhanced in Sirt6BAC mice compared to wild-type controls. Insulin-stimulated glucose uptake was increased in Sirt6BAC mice in both gastrocnemius and soleus muscle, but not in brain, interscapular brown adipose, or epididymal adipose tissue. Insulin-induced p-AKT/AKT ratio was increased in gastrocnemius muscle of Sirt6BAC mice compared to wild-type controls. Conclusions: Our data indicate that moderate, physiological overexpression of SIRT6 enhances insulin sensitivity in skeletal muscle and liver, engendering protective actions against diet-induced T2DM. Hence, the present study provides support for the anti-T2DM effect of SIRT6 and suggests SIRT6 as a putative molecular target for anti-T2DM treatment.
AB - Objective: Available treatment for obesity and type 2 diabetes mellitus (T2DM) is suboptimal. Thus, identifying novel molecular target(s) exerting protective effects against these metabolic imbalances is of enormous medical significance. Sirt6 loss- and gain-of-function studies have generated confounding data regarding the role of this sirtuin on energy and glucose homeostasis, leaving unclear whether activation or inhibition of SIRT6 may be beneficial for the treatment of obesity and/or T2DM. Methods: To address these issues, we developed and studied a novel mouse model designed to produce eutopic and physiological overexpression of SIRT6 (Sirt6BAC mice). These mutants and their controls underwent several metabolic analyses. These include whole-blood reverse phase high-performance liquid chromatography assay, glucose and pyruvate tolerance tests, hyperinsulinemic-euglycemic clamp assays, and assessment of basal and insulin-induced level of phosphorylated AKT (p-AKT)/AKT in gastrocnemius muscle. Results: Sirt6BAC mice physiologically overexpress functionally competent SIRT6 protein. While Sirt6BAC mice have normal body weight and adiposity, they are protected from developing high-caloric-diet (HCD)-induced hyperglycemia and glucose intolerance. Also, Sirt6BAC mice display increased circulating level of the polyamine spermidine. The ability of insulin to suppress endogenous glucose production was significantly enhanced in Sirt6BAC mice compared to wild-type controls. Insulin-stimulated glucose uptake was increased in Sirt6BAC mice in both gastrocnemius and soleus muscle, but not in brain, interscapular brown adipose, or epididymal adipose tissue. Insulin-induced p-AKT/AKT ratio was increased in gastrocnemius muscle of Sirt6BAC mice compared to wild-type controls. Conclusions: Our data indicate that moderate, physiological overexpression of SIRT6 enhances insulin sensitivity in skeletal muscle and liver, engendering protective actions against diet-induced T2DM. Hence, the present study provides support for the anti-T2DM effect of SIRT6 and suggests SIRT6 as a putative molecular target for anti-T2DM treatment.
KW - Diabetes
KW - Glucose homeostasis
KW - Insulin sensitivity
KW - SIRT6 overexpression
KW - Sirtuin
UR - http://www.scopus.com/inward/record.url?scp=84945305740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945305740&partnerID=8YFLogxK
U2 - 10.1016/j.molmet.2015.09.003
DO - 10.1016/j.molmet.2015.09.003
M3 - Article
C2 - 26629408
AN - SCOPUS:84945305740
SN - 2212-8778
VL - 4
SP - 846
EP - 856
JO - Molecular Metabolism
JF - Molecular Metabolism
IS - 11
ER -